Literature DB >> 17448953

Risk assessment in haemotopoietic stem cell transplantation: disease and disease stage.

Aristeidis Chaidos1, Ed Kanfer, Jane F Apperley.   

Abstract

This chapter addresses the impact of the disease and disease status on the outcome of stem-cell transplantation. In consideration of the other topics addressed within this volume we have elected to focus on allogeneic rather than autologous transplantation. Furthermore we have not tried to be comprehensive and discuss the role of disease status in all conditions amenable to allografting, but rather to review the evidence that exists for selected haematological malignancies. Where possible we have made some clear recommendations, but where evidence is less clear we have indicated the ongoing controversies.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17448953     DOI： 10.1016/j.beha.2006.10.003

Source DB:  PubMed          Journal:  Best Pract Res Clin Haematol        ISSN： 1521-6926            Impact factor:   3.020


  9 in total

1.  Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective.

Authors:  Marcie Tomblyn; Tom Chiller; Hermann Einsele; Ronald Gress; Kent Sepkowitz; Jan Storek; John R Wingard; Jo-Anne H Young; Michael J Boeckh; Michael A Boeckh
Journal:  Biol Blood Marrow Transplant       Date:  2009-10       Impact factor: 5.742

Review 2.  Myeloablative radioimmunotherapy in conditioning prior to haematological stem cell transplantation: closing the gap between benefit and toxicity?

Authors:  Inga Buchmann; Ralf G Meyer; Walter Mier; Uwe Haberkorn
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-01-08       Impact factor: 9.236

3.  Improvement of overall survival after allogeneic hematopoietic stem cell transplantation for children and adolescents: a three-decade experience of a single institution.

Authors:  E Brissot; F Rialland; X Cahu; M Strullu; N Corradini; C Thomas; N Blin; X Rialland; E Thebaud; P Chevallier; P Moreau; N Milpied; J L Harousseau; F Mechinaud; M Mohty
Journal:  Bone Marrow Transplant       Date:  2015-12-07       Impact factor: 5.483

4.  Cost-utility analysis of inotuzumab ozogamicin for relapsed or refractory B cell acute lymphoblastic leukemia from the perspective of Taiwan's health care system.

Authors:  Tsung-Ying Lee; Hsuan-Ying Chen; Tsai-Yun Chen; Sin-Syue Li; Wei-Tse Fang; Yao-Chun Wen; Yu-Wen Lo; Huang-Tz Ou
Journal:  Eur J Health Econ       Date:  2020-06-06

5.  Infectious disease screening among stem cell transplant donors: An Institutional experience in Saudi Arabia.

Authors:  Omar Alsuhaibani; Winston Costa Pereira; Mohammed Tareeqanwar; Nora El Khizzi; Saadia Bakheswain; Amira Shaker; Ghaleb Elyamany
Journal:  Ann Neurosci       Date:  2015-04

6.  Preconditioning serum levels of endothelial cell-derived molecules and the risk of posttransplant complications in patients treated with allogeneic stem cell transplantation.

Authors:  Roald Lindås; Tor Henrik Andersson Tvedt; Kimberley Joanne Hatfield; Håkon Reikvam; Oystein Bruserud
Journal:  J Transplant       Date:  2014-10-08

7.  The pretransplant systemic metabolic profile reflects a risk of acute graft versus host disease after allogeneic stem cell transplantation.

Authors:  Håkon Reikvam; Kimberley Hatfield; Øystein Bruserud
Journal:  Metabolomics       Date:  2015-11-16       Impact factor: 4.290

8.  Association of Pre-Transplant Angiopoietin-2 Index with the Risk of Acute Graft-Versus-Host Disease after Hematopoietic Stem Cell Transplantation

Authors:  Özlem Satırer; İnci Cevher Zeytin; Berna Alkan; Jale Karakaya; Duygu Çetinkaya; Fatma Visal Okur
Journal:  Turk J Haematol       Date:  2021-10-07       Impact factor: 1.831

9.  Cost-Effectiveness of Inotuzumab Ozogamicin Compared to Standard of Care Chemotherapy for Treating Relapsed or Refractory Acute Lymphoblastic Leukaemia Patients in Norway and Sweden.

Authors:  I van Oostrum; T A Russell-Smith; M Jakobsson; J Torup Østby; B Heeg
Journal:  Pharmacoecon Open       Date:  2021-07-26
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.